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Abstract
Aim—The hippocampus is considered a key region in schizophrenia pathophysiology, but the 
nature of hippocampal subregion abnormalities and how they contribute to disease expression 
remain to be fully determined. This study reviews findings from schizophrenia hippocampal 
subregion volumetric and physiological imaging studies published within the last decade.
Methods—The PubMed database was searched for publications on hippocampal subregion 
volume and physiology abnormalities in schizophrenia and their findings were reviewed.
Results—The main replicated findings include smaller CA1 volumes and CA1 hyperactivation in 
schizophrenia, which may be predictive of conversion in individuals at clinical high risk of 
psychosis, smaller CA1 and CA4/DG volumes in first-episode schizophrenia, and more 
widespread smaller hippocampal subregion volumes with longer duration of illness. Several 
studies have reported relationships between hippocampal subregion volumes and declarative 
memory or symptom severity.
Conclusions—Together these studies provide support for hippocampal formation circuitry 
models of schizophrenia. These initial findings must be taken with caution as the scientific 
community is actively working on hippocampal subregion method improvement and validation. 
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Further improvements in our understanding of the nature of hippocampal formation subregion 
involvement in schizophrenia will require the collection of structural and physiological imaging 
data at submillimeter voxel resolution, standardization and agreement of atlases, adequate control 
for possible confounding factors, and multi-method validation of findings. Despite the need for 
cautionary interpretation of the initial findings, we believe that improved localization of 
hippocampal subregion abnormalities in schizophrenia holds promise for the identification of 
disease contributing mechanisms.
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1 | INTRODUCTION
The hippocampus, which plays a key role in emotion, stress, and declarative memory, has 
long been considered a key region in the pathophysiology of schizophrenia1–3 and findings 
such as smaller hippocampal volume,4–6 lower episodic memory performance,7,8 and 
hippocampal physiological abnormalities9–11 are well established in individuals with 
schizophrenia when compared to controls. These abnormalities are also observed in relatives 
of individuals with schizophrenia,12–15 suggesting possible genetic influences. The illness 
stage at which these abnormalities arise has not been fully clarified, but research suggests 
that lower whole hippocampal volume is present at psychosis onset but may not predate the 
illness.16 Most schizophrenia-related brain imaging studies published to date, however, have 
focused on the overall hippocampus, or the anterior and posterior hippocampus17,18 based 
on the view that the anterior hippocampus serves anxiety-related and the posterior 
hippocampus serves spatial navigation and memory-related behaviors.19 The hippocampal 
formation, however, is comprised of several subregions, including the dentate gyrus (DG), 
cornu ammonis (CA) 1–4, the subiculum (pre-, para-, and pro), and the entorhinal cortex 
(EC). The EC provides input to the hippocampus and connects via the perforant pathway to 
the DG, which connects via the mossy fiber pathway to CA3, which connects via the 
schaffer collateral pathway to CA1. These regions form the trisynaptic pathway. CA1 
projects to the subiculum, which is the major hippocampal output region of the 
hippocampus. Both CA1 and subiculum also have bidirectional connections with the EC [for 
review, see20].
Several models of hippocampal formation circuitry pathology in schizophrenia have been 
proposed.20–25 Benes21 suggested that schizophrenia is associated with GABAergic 
dysfunction in areas CA2/3 of the trisynaptic pathway. Lisman and Grace22 hypothesized a 
hyperdopaminergic state in schizophrenia due to an abnormally functioning loop connecting 
the subiculum to the ventral tegmental area; they suggest that this may result in a mismatch 
between lowered cortical input to CA1, representing sensory reality, and CA3 input to CA1, 
representing predicted information. Behrendt23 hypothesized that increased CA3 excitability 
may produce hallucinations. Tamminga et al24 model posits a primary deficit in the DG with 
reduced input to CA3 and predicts that individuals with schizophrenia show a deficit in DG-
dependent pattern separation, required for the formation of nonoverlapping memory 
representations, and an increase in CA3/CA1-dependent pattern completion, required for 
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associate retrieval based on partial information; two processes critically important for the 
formation and retrieval of declarative episodic memories that may play a role in generating 
psychotic symptoms including hallucinations and delusions. Small and colleagues’ 2013 
model posits a primary deficit in the hippocampal CA1 region, thought to be involved in the 
integration of multiple sources of input.20 Taken together, these models suggest primary 
involvement of different hippocampal subregions in schizophrenia pathophysiology. Here, 
we review structural and physiological studies of hippocampal subregions that may provide 
evidence for or against these schizophrenia hippocampal formation circuitry models by 
addressing questions such as: (a) what subregions are affected; (b) at what illness stage age 
are they affected; (c) how are they influenced by genetic and environmental factors; (d) are 
they unique to schizophrenia; (e) are they associated with cognitive performance, and (f) are 
they associated with symptoms?
2 | METHODS
We searched the PubMed database using the terms “hippocampal subfield[s]” OR 
“hippocampal subregion[s]” AND “schizophrenia” OR “psychosis,” as well as “cornu 
ammonis,” “CA1,” “CA2,” “CA3,” “CA4,” “dentate gyrus,” “DG,” “molecular layer,” 
“ML,” or “subiculum” AND “schizophrenia” AND “volume” OR “fMRI.” We combined the 
search results, removed duplicates, and manually reviewed titles and abstracts from 1373 
manuscripts published after 2008—when the first automated method for hippocampal 
subfield volume estimation was published26—inclusive and prior to November 9, 2017 
(Figure 1). We excluded any manuscripts based on shape methods based on primary interest 
in hippocampal subregion volume and physiology findings and because shape findings are 
difficult to summarize. We identified 13 relevant structural imaging publications27–39 (Table 
1), and 3 relevant physiological imaging publications40–42 (Table 2).
3 | RESULTS
3.1 | Structural abnormalities in hippocampal subregions in schizophrenia
Several high-resolution automated and manual methods have been developed to compute 
hippocampal formation subregion or subfield volumes.43–45 Van Leemput et al26,46 first 
published method and atlas implemented in FreeSurfer morphometry package versions prior 
to 6.0,47,48 segments the hippocampus into CA4/DG, CA2/3, CA1, subiculum, 
presubiculum, fimbria, posterior hippocampus, and hippocampal-fissure regions based on a 
high-resolution T1-weighted image. More recently, Iglesias et al49 published an updated 
method and ex vivo atlas that is implemented in FreeSurfer 6.0, which segments the 
hippocampus into granule cell-molecular layer-dentate gyrus (GC-ML-DG), CA3, CA4, 
subiculum, presubiculum, parasubiculum, alveus, fimbria, hippocampal-amygdaloid 
transition region (HATA), and hippocampal tail regions. The atlas was updated because it 
was noted that the earlier atlas underestimated the volume of CA1 and that subregions were 
segmented along the entire longitudinal axis of the hippocampus, suggesting that additional 
rigor in atlas creation was warranted.50
Most schizophrenia imaging studies using FreeSurfer to estimate hippocampal subregion 
volumes published to date have employed the first method and atlas.27,28,30–34 Three 
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FreeSurfer studies have used the second method with the updated hippocampal subregion 
segmentation atlas run on top of the FreeSurfer 5.3 whole hippocampal segmentation.35,36,39
Another method, Automated Segmentation of Hippocampal Subfields (ASHS),51,52 requires 
a high-resolution coronal T2-weighted image in addition to a high-resolution T1-weighted 
image. Its initial atlas segmented the hippocampus into CA1–3, DG, EC, and 
parahippocampal gyrus. Several additional atlases are provided with the software and 
researchers can also build their own based on manual tracings (http://picsl.upenn.edu/
software/ashs). This method has only been employed by a single schizophrenia study 
published to date.30 Finally, two studies performed manual tracings to compare hippocampal 
formation subregion volumes between individuals with schizophrenia or at clinical high-risk 
and healthy controls,37,41 and one study rated granule cell layer contrast (visibility) based on 
high-resolution brain scans acquired at 7T between individuals with schizophrenia and 
healthy controls.29
The first study of hippocampal subregion volumes in schizophrenia by Kühn et al27 found a 
negative correlation between bilateral CA2/3 and CA1 volumes and positive symptoms in 21 
subjects with schizophrenia with a mean duration of illness of 7.8 years. In contrast, negative 
symptoms were not found to be associated with CA subfield volumes. This study provides 
initial suggestive evidence for an association between CA2–3/CA1 and positive symptoms in 
schizophrenia. The study was conducted in predominantly medicated patients (19/21 on 
atypical antipsychotics) and did not compare subfield volumes between patients with 
schizophrenia and healthy controls.
Francis and colleagues (2013) found lower bilateral subicular volumes in 46 offspring of 
parents with schizophrenia (familial high-risk subjects) compared with 29 healthy 
volunteers.27,28 They also reported significant positive correlations between left and right 
subicular volumes and Wechsler Memory Scale immediate recall and learning slope 
measures of declarative memory in the offspring of parents with schizophrenia but not in the 
healthy controls. Importantly, among the familial high-risk subjects, 27 of 46 had a diagnosis 
of major depressive disorder (MDD) and 9 of 46 had a diagnosis of anxiety disorder (AD) 
relative to 2 of 30 for each of these two diagnoses in the control group. Hippocampal 
subregion volumes between familial high-risk subjects with MDD, AD, and without DSM-
IV diagnoses were not compared, leaving the possibility that the observed lower subicular 
volumes between the offspring of parents with schizophrenia and healthy control groups 
could be predominantly driven by the subjects with MDD/AD diagnoses. In addition, 
parental socioeconomic status was significantly higher in the offspring compared with the 
healthy control group and was not controlled for. Finally, a reference suggests that a FLASH 
sequence with a resolution of 1.17 × 1.17 × 8 mm53 was used and it is not clear whether that 
is sufficient for accurate hippocampal subregion segmentation.
Mathew et al30 published the first study comparing hippocampal subregion volumes between 
individuals with schizophrenia (mean duration of illness 15.67 years) and healthy controls. 
They found lower bilateral CA1, CA2/3, CA4/DG, presubiculum, and subiculum volumes in 
219 individuals with schizophrenia compared to 337 controls. Similar effects were observed 
in individuals with schizoaffective disorder (n = 142), though individuals with bipolar 
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disorder (n = 188) only showed significantly lower bilateral CA2/3, left presubiculum, and 
right CA4/DG and subiculum volumes and overall smaller effect sizes than the other two 
groups. Unfortunately, despite known and noted lack of hippocampal volume54 and other 
gray matter deficiencies55 in lithium-treated individuals with bipolar disorder, the authors 
did not report findings and effect sizes for lithium-treated (n = 53) and non-lithium-treated 
(n = 135) bipolar disorder subjects separately. They further found that the volumes of the 
bilateral subiculum and the left presubiculum were negatively correlated with positive 
symptom severity, that the right subiculum negatively correlated with delusion item ratings, 
and that left CA2/3, CA4/DG, presubiculum, and subiculum volumes negatively correlated 
with hallucination item ratings. In schizophrenia, bilateral CA1, CA2/3, CA4/DG, 
presubiculum, and subiculum showed significant positive correlations with the BACS (Brief 
Assessment of Cognition in Schizophrenia56) composite cognitive score. Left CA1, CA2/3, 
CA4/DG, and subiculum also showed significant positive correlations with the BACS list 
learning score; a verbal declarative memory measure.30 No significant correlations were 
observed in the healthy controls. Together, these findings suggest that multiple hippocampal 
subregion volumes may be affected in schizophrenia and schizoaffective disorder, with 
possibly the strongest effects in CA2/3, CA4/DG and the subiculum, and that they are 
associated with higher positive symptom severity and lower declarative memory 
performance. The study did not examine possible relationships between hippocampal 
subregion volumes and duration of illness.
A study by Haukvik et al32 compared 210 individuals with schizophrenia spectrum disorders 
(mean duration of illness 8.2 years), 192 individuals with bipolar spectrum disorders (mean 
duration of illness 7.8 years), and 300 healthy controls. They found lower bilateral CA2/3, 
CA4/DG, presubiculum, and subiculum, as well as right CA1 volumes in individuals with 
schizophrenia when compared to controls. Similar effects, except for no differences in 
presubiculum volume, were observed in individuals with bipolar disorder when compared to 
healthy controls; though bilateral subiculum and right presubiculum volumes appeared 
significantly lower in individuals with schizophrenia compared to individuals with bipolar 
disorder. Furthermore, subiculum volume was positively correlated with verbal memory 
performance (free and cued recall) in the bipolar and control but not schizophrenia subjects. 
Finally, subiculum volume was negatively associated with negative symptom severity in 
individuals with schizophrenia. An additional analysis controlling for total hippocampal 
volume only found larger CA1 volume in individuals with schizophrenia compared to 
controls. This finding suggests a lack of anatomical specificity in hippocampal subregion 
volume deficiencies, possibly with CA1 being the least affected in individuals with 
schizophrenia; though it is also possible that the subregion segmentations were 
predominantly driven by template priors and therefore highly correlated with total 
hippocampal volume. It is further noted that the CA1 volume estimates must be interpreted 
with caution because they are likely underestimated by the method. The findings further 
suggest that subicular outflow regions may be more affected in schizophrenia when 
compared to bipolar disorder.
Kawano et al31 conducted the first assessment of hippocampal subregion volume 
abnormalities in first-episode psychosis. In a 6-month longitudinal follow-up study, they 
compared hippocampal subregion volumes between individuals with first-episode (n = 19; 
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first contact for psychosis treatment and <1 month of treatment), sub-chronic (n = 6; 6 
months < illness duration <5 years), or chronic schizophrenia (n = 9; illness duration > 5 
years) and fifteen healthy controls. They found lower left CA2/3 and CA4/DG volumes in 
the first-episode, sub-chronic, and chronic schizophrenia groups compared to controls with 
effect sizes scaling with disease chronicity and strongest for the CA4/DG. Moreover, they 
found a steeper rate of decline in CA4/DG in first-episode patients (n = 10) compared with 
healthy controls (n = 12). In addition, they found that left CA2/3 and CA4/DG volumes were 
negatively correlated with duration of illness and negative symptom severity. While this 
study has a relatively small sample size, its findings suggests that CA2/3 and CA4/DG 
volume deficiencies may be present at illness onset and may progress with illness duration.
Hýža et al,33 in a 4-year longitudinal study found enlarged left CA1 volume in 58 
individuals with first-episode schizophrenia (with a mean duration of untreated psychosis of 
7.23 months; 38 with follow-up clinical data) when compared to 58 healthy controls. They 
also found a trend-level negative correlation between duration of untreated psychosis and 
CA2/3 volume and a positive correlation between right CA1 volume and positive symptom 
severity. The findings from this study, in particular enlarged CA1 and the positive correlation 
between CA1 volume and positive symptom severity are hard to interpret. The authors 
provide no table of raw mean subregion volumes that can be examined to see if volume 
estimates are in line with those found in other reports. The manuscript depicts a normalized 
CA1 volume but does not provide the denominator region. Hence, the larger CA1 volume 
could suggest that CA1 volume was less affected than that of the denominator region used in 
the normalization. It is also unclear whether the patient and control groups were matched for 
demographic variables such as parental socioeconomic status or education level.
In a 3-month follow-up study, Papiol et al38 assessed changes in hippocampal subregion 
volumes in 20 multi-episode schizophrenia patients (mean number of hospitalization of 4.2) 
and 23 healthy controls who performed aerobic exercise with cognitive remediation training 
compared to 21 multi-episode schizophrenia patients who performed table soccer (control 
intervention) with cognitive remediation training. They found that a higher schizophrenia 
genetic risk burden (assessed based on a Psychiatric Genomics Consortium derived 
polygenic risk score [PRS]57) was associated with less volume increase or decrease in 
DG/CA4 volume during the intervention in the patients who performed aerobic exercise 
with cognitive remediation training but not in the two control groups. These findings provide 
initial evidence for a gene-environment interaction effect on DG plasticity in schizophrenia 
but must be regarded with caution as they warrant replication in a larger sample.
Ho et al35,36 conducted the first study using FreeSurfer with the new ex vivo hippocampal 
subregion atlas. They assessed 155 individuals with schizophrenia—with a mean duration of 
illness of 7 years—along with 79 healthy comparisons subjects (study 1), as well as 46 
individuals with schizophrenia—with a mean duration of illness of 18 years—along with 46 
healthy comparisons subjects (study 2); follow-up scans were available from 34 individuals 
with schizophrenia (mean of 4.52 years apart) and 41 healthy comparison (mean of 5.26 
years apart) subjects from study 1. Compared with controls, they reported significantly 
smaller left CA1 volume in schizophrenia in study 1, and more widespread lower volume in 
bilateral ML_GC_DG (reported as GCL), CA1, CA3, CA4, ML, subiculum, and tail regions 
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in schizophrenia in study 2. In a secondary analysis of a study 1 subsample, they found 
smaller bilateral CA1 and right ML_GC_DG volumes in patients within their first 5 years of 
illness (n = 53) compared to controls (n = 61). The analysis of the follow-up sample showed 
smaller CA1 volumes at baseline and significant reductions over time in bilateral CA1 and 
ML_GC_DG, and right ML and CA3 volumes. However, in addition to a longer duration of 
illness, sample 2 also had a higher daily dose of antipsychotic medication and higher 
symptom severity. While they found no significant relationships between hippocampal 
subregion volumes and medication dose or symptom severity, they found that CA1 volumes 
were negatively associated with duration of illness. Moreover, in the longitudinal sample, 
rate of reduction in hippocampal subregion volumes correlated with overall worsening of 
general symptom severity; more specifically, rate of reduction in left CA1 volume correlated 
with rate of worsening of negative symptom severity. They concluded that in the early 
phases of illness, individuals with schizophrenia show lower CA1 volumes and that during 
the course of the illness, this focal atrophy extends to other hippocampal subregions 
including the CA3 and ML_GC_DG regions. Further, hippocampal subregion volumes 
decline with longer duration of illness and worsening of symptoms. This study has several 
strengths, it uses the updated and more accurate hippocampal subregion template, it includes 
short- and long duration of illness samples, and longitudinal data from a subsample. The 
authors list a rate of change of hippocampal subregion volume loss of 2%-6% per year. This 
rate of change seems rather high as when assuming linearity, after 5 years of illness, patients 
would have lost 10%-30% of their hippocampal volumes which is more than the mean 
reported in most studies to date.
More recently, Baglivo et al39 reported lower bilateral CA1, CA4, and ML_GC_DG, and 
lower left CA3 and ML volumes comparing 58 individuals with first-episode psychosis and 
76 healthy controls using FreeSurfer’s new ex vivo atlas. No significant correlations with 
clinical variables were observed.
In a second longitudinal study, Ho et al35 assessed hippocampal subregion volumes using the 
same method in 93 individuals at ultra high risk (UHR) of psychosis (12 UHR who 
converted to clinical psychosis, 40 whose symptoms persisted, and 41 whose symptoms 
remitted) and 54 healthy controls at baseline, 1-year, and 2-year follow-up, or at time of 
conversion. They found greater decline in CA1 volume in UHR subjects whose symptoms 
persisted or who converted to psychosis than in those whose symptoms remitted and healthy 
controls. Moreover, rate of reduction in CA1 volume but not any other sub region was 
associated with overall increased symptom severity. Among all the other hippocampal 
subregions, only the right CA3 showed a steeper reduction in UHR subjects who did not 
remit when compared to controls though this effect was no longer significant when 
antidepressant and benzodiazepine medication treatment were statistically controlled for. 
Additionally, UHR subjects were never treated with antipsychotic or mood stabilizers and 
did not have histories of substance abuse suggesting disease-related rather than comorbid or 
treatment-related effects on the changes in CA1 volumes. This study replicates the earlier 
finding of a steeper rate of change for hippocampal subregion volumes, specifically in CA1, 
in CHR subjects.36 Together with their prior report, these findings provide compelling 
evidence for primary involvement of CA1 early in schizophrenia pathogenesis.
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To date, the only study that has assessed hippocampal subregion volumes using ASHS51,52 
has been reported by Ota and colleagues (2017). They assess 20 individuals with 
schizophrenia, 36 with major depressive disorder (MDD), and 35 healthy volunteers with 
high-resolution T1-weighted and high-resolution T2-weighted scans (perpendicular to the 
longitudinal axis of the hippocampus). They found lower CA1 volumes in schizophrenia 
compared to control subjects, and lower DG volumes in schizophrenia compared to control 
and unmedicated MDD subjects. This study makes an important contribution by replicating 
CA1 and DG volume abnormalities in an independent sample using a different and well-
regarded hippocampal subregion segmentation method.
The first study that performed manual tracings of hippocampal subregion volumes assessed 
individuals at clinical high risk (CHR) of psychosis41 and will be addressed in the 
physiology section of the review. A second study that performed manual tracings of 
hippocampal subregions, by Rhindress et al,37 found that DG/CA4 volume decreased while 
subiculum volume increased in a sample of 29 individuals with first-episode psychosis, 
treated for 12-weeks with either risperidone or aripiprazole, relative to 29 healthy volunteers 
in a double-blind randomized clinical trial. Interestingly, percent DG/CA4 of total 
hippocampus volume change showed a quadratic relationship with chlorpromazine 
equivalent dose, perhaps suggesting that the DG/CA4 decreases were predominantly present 
in individuals with the lowest and the highest treatment doses. While the larger reductions in 
DG/CA4 volume in first-episode psychosis subjects compared to controls are interesting, it 
is unclear to what extent they are due to the antipsychotic treatment or part of the normal 
course of the illness.
Finally, the first ultra high-resolution structural imaging study performed at 7T with a voxel 
size of 0.238 × 0.238 × 1.5 mm (20% gap) found lower mean dentate gyrus granule cell 
layer integrity (visibility) when comparing scans from 16 individuals with schizophrenia 
(mean duration of illness of 20 years) with 15 age- and gender-matched controls.29 This 
study is unique and suggests additional avenues to pursue using high-field, high-resolution, 
imaging of hippocampal subregions.
3.2 | Physiological abnormalities in hippocampal subregions in schizophrenia
With regard to physiological abnormalities, three studies have reported on hippocampal 
subregion cerebral blood volume in schizophrenia during rest.40–42 Using a gadolinium-
enabled cerebral blood flow (CBV) mapping technique, Schobel et al40 measured EC, DG, 
CA3, CA1, and subiculum CBV in 18 individuals with schizophrenia or schizoaffective 
disorder (mean duration of illness 10.5 years) and 18 demographically similar controls. They 
also assessed regional CBV in 18 individuals at CHR for psychosis, of which 7 converted to 
a schizophrenia spectrum disorders after a 2-year follow-up. They found higher CA1 CBV 
in the individuals with schizophrenia or schizoaffective disorder when compared to the 
healthy volunteers. They also found higher CA1 CBV in the CHR subjects who converted vs 
those who did not. Moreover, CA1 CBV was positively correlated with symptom severity in 
the combined clinical subject group (schizophrenia and CHR), with the strongest association 
with delusional symptom severity; CA1 CBV was also positively associated with delusion 
severity within each clinical group. Within the CHR group, CA1 CBV was also positively 
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associated with total negative symptom, social dysfunction, and avolition severity. Finally, 
only 1 out of 7 CHR converters received antipsychotic medication making it unlikely that 
the observed higher CA1 CBV was due to effects of antipsychotic treatment. This study’s 
major strength is that it shows higher CA1 CBV in schizophrenia with a replication in an 
independent sample of individuals at CHR for psychosis.
In a second study, using the same technique, Schobel et al41 measured EC, DG, CA3, CA1, 
and subiculum CBV and hippocampal subregion volumes in 25 individuals at CHR for 
psychosis at baseline and 20 of the same subjects during follow-up with a mean interscan 
interval of 2.4 years. During follow-up, 10 of the 25 subjects developed a psychotic disorder. 
At baseline, CHR subjects who developed a psychotic disorder had higher bilateral mean 
CA1 CBV when compared to subject who did not. When each hemisphere was considered 
separately, higher left but not right hemisphere CA1 CBV was found. At follow-up, CHR 
subjects who developed psychosis showed CBV increases in the subiculum only, while CA1 
CBV did not increase beyond the elevation observed at baseline. Moreover, left hemisphere 
CA1 CBV predicted time to psychosis in a Cox regression analysis; this was found even 
when known symptom-based predictors were included in the statistical model. 
Morphological analyses also showed significant loss of whole hippocampal volume, in 
particular CA1 and subiculum volumes, at follow-up, compared to baseline, in CHR 
converters compared to non-converters. This study found no effect of antipsychotic 
treatment on the regional hippocampal CBV or morphology. They further found that a larger 
increase in left anterior CA1 CBV was associated with a larger decrease in hippocampal 
volume at follow-up. Further, a shape analysis showed that a posterior to anterior gradient in 
CA1 hyperactivity was associated with a posterior to anterior gradient in CA1 volume loss. 
Of note, the authors showed that acute injection of ketamine in mice resulted in a significant 
increase in CA1 and subiculum but not EC, CA3, and DG CBV, findings that mimic the 
observation in the UHR converters. This study suggests that high left anterior CA1 CBV 
spreads to the subiculum after illness onset. Importantly, the reported translational work in 
mice provides a mechanistic link between high CA1 CBV, the presence of extracellular 
glutamate, and hippocampal volume loss. It must be noted that, while the findings are 
compelling, this study does not represent a fully independent replication of Schobel et al40 
findings in subjects at CHR for psychosis as 18/25 CHR subjects overlapped with the prior 
study. Further, it has been noted by Talati et al42 that the higher CA1 CBV findings were 
based on only a single slice of left anterior CA1 averaged across both hemispheres. This 
report, however, makes a unique a contribution to the research literature with the inclusion of 
longitudinal data, and it importantly provides a stellar example of how the integration of 
rodent work can further our understanding of mechanisms underlying human brain imaging 
findings.
Talati et al42 conducted a gadolinium-enhanced, T1-weighted, steady state brain mapping 
study comparing 15 individuals with schizophrenia or schizoaffective disorder (mean 
duration of illness of 8.47 years) with 15 demographically similar controls. They found 
lower CA1 than CA2/3 CBV in controls but similar CA1 and CA2/3 CBV in individuals 
with schizophrenia or schizoaffective disorder. Between group comparisons showed 
marginally higher CA1 CBV in the patients compared to the controls (P = 0.06; Cohen’s d = 
0.63). Anterior CA1 CBV did not correlate significantly with symptom severity. This study 
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provides a partial replication by an independent group of the higher CA1 CBV reported in 
the first two studies, though did not replicate previously observed associations with 
symptom severity.
4 | DISCUSSION
This study reviews hippocampal subregion volume and physiology findings to assess the 
status of the field with regard to the following questions: (a) what subregions are affected; 
(b) at what illness stage are they affected; (c) how are they influenced by genetic and 
environmental factors; (d) are they unique to schizophrenia; (e) are they associated with 
cognitive performance, and (f) are they associated with symptoms?
Twelve studies, comprising 15 samples—including 1 familial high risk, 2 clinical high risk, 
and 4 first-episode—examined schizophrenia-associated hippocampal subregion volume 
deficiencies. Overall, the subregions that show the most prominent volume alteration in 
schizophrenia are CA1,30,32,34,35,39,41 CA2/3,30–32,34–36,39 DG/CA4,30–32,34–36,39 and 
subiculum.28,30,32,36 The two longitudinal clinical high-risk studies published to date 
replicate larger decreases in CA1 volume in those who convert to psychosis when compared 
with those who do not and healthy controls35,41; one shows an additional decrease in CA2/3 
and the other in subiculum volumes.35 In addition, in all but two studies,31,33 the more 
chronic schizophrenia samples30,32,34,36 showed more hippocampal subregion deficiencies 
than the first-episode schizophrenia samples,31,37,39 and all31,36,37 but one longitudinal 
study33 found further volume decline in subregion volumes after illness onset.
Three studies, comprising 4 samples (3 independent)—including 2 chronic schizophrenia 
and 1 clinical high risk for psychosis—reported high CA1 CBV in schizophrenia40,42 or in 
CHR converters compared to controls.40,41 Importantly, high CA1 CBV was associated with 
overall hippocampal and CA1 volume loss and initial evidence of an underlying mechanism 
involving extracellular glutamate was reported on.41
Together, these findings indicate that the deficits in the DG-CA3-CA1-subiculum circuit 
may contribute to the emergence of psychosis, though the degree of alteration and 
contribution for each of these regions to psychosis may depend on the stage of illness. The 
findings of fewer regional deficiencies in clinical high risk and first-episode schizophrenia 
subjects compared to chronic schizophrenia subjects, with the most evidence for early 
replicated CA1 volume deficiency36,41 and high CA1 CBV40,41 during the prodromal phase 
and in addition replicated CA4/DG volume deficiency at first-episode,31,37,39 suggest that 
regional hippocampal volume deficiencies may be larger than total hippocampal volume 
deficiencies. This interpretation fits well with the observation that overall hippocampal 
volume deficits were found not present prior to illness onset, to emerge in first-episode 
schizophrenia, and to be clearly present in chronic schizophrenia.16
With regard to genetic and environmental influences, only a single study in individuals at 
familial high risk for schizophrenia showed smaller subiculum volumes in high- vs low-risk 
subjects.28 An additional study found that higher schizophrenia polygenic risk scores 
predicted less volume increase or possibly volume decrease in CA4/DG volume in an 
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exercise trial.38 No further family or genetic association studies examining hippocampal 
subregions in schizophrenia have been reported on, though hippocampal subregion volumes 
were shown to be heritable in healthy individuals.58,59
Two studies compared hippocampal subregion volumes between schizophrenia and bipolar 
disorder,30,32 with one reporting less,30 and the other reporting similar hippocampal 
subregion volume deficiencies in bipolar disorder compared to schizophrenia.32 The later 
study found that presubiculum and subiculum volumes were more affected in schizophrenia.
32
 Another study found lower CA1 volumes in schizophrenia compared to controls subjects, 
and lower DG volumes in schizophrenia compared to control and unmedicated subjects with 
major depressive disorder.34 Clearly, these findings warrant replication. Cross-disorder 
comparisons are critically important to determine whether any of the observed hippocampal 
subregion anomalies are disease-specific or generic to multiple psychiatric disorders and 
perhaps due to common underlying risk factor such as stress.21 Based on our literature 
review, no cross-disorder studies of hippocampal subregion physiology have been 
conducted.
With regard to contributions of hippocampal subregions to declarative memory deficiencies 
observed in schizophrenia, one study reported a significant positive correlation between 
subiculum volume and declarative memory performance in familial high-risk subjects,28 
while another found significant positive correlations between CA1, CA2/3, CA4/DG and 
subiculum volumes and episodic memory performance in individuals with schizophrenia.
28,30
 While encouraging in suggesting potential differential involvement of subregion 
abnormalities in observed declarative memory performance abnormalities in schizophrenia, 
these findings are by no means conclusive and require further investigation.
Several studies have shown significant correlations between CA1 and CA2/3 volumes27,30 
and one study between presubiculum and subiculum volumes and positive symptom severity.
30
 Additionally, three studies found a relationship between hippocampal subregion volumes 
and negative symptoms but each with a different region, namely subiculum,32 CA2/3 and 
CA4/DG,31,34 or CA2.31 Finally, CA1 CBV has been found to be associated with overall, 
positive, and negative symptom severity40 though these findings were not replicated in a 
more recent report.42
In sum, the structural and physiological imaging studies of hippocampal subregion 
abnormalities in schizophrenia published to date provide the most consistent evidence for 
the involvement of CA1 early on in the disease process. These findings support Small and 
colleagues (2011) model20,29 of hippocampal subregion dysfunction in schizophrenia. 
However, ultra high-resolution structural imaging at 7T has provided initial in-vivo evidence 
for lower dentate gyrus granule cell layer integrity in schizophrenia,20 and lower CA4/DG or 
GC-ML-DG or DG volumes have been replicated and shown to be present in individuals 
with first-episode schizophrenia,31,37 and may be unique to schizophrenia when compared 
major depressive disorder,30 also providing relatively strong support from volumetric studies 
for Tamminga and colleagues’ (2010) model of hippocampal subregion dysfunction in 
schizophrenia.24,25 The observations of lower pre/subiculum volumes in schizophrenia when 
compared to bipolar disorder32,41 and the presence of subiculum hyperactivation after 
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psychosis onset41 provide some initial in-vivo imaging evidence for subiculum involvement 
in schizophrenia in support of the Lisman and Grace’s22 model. Two studies have shown 
significant negative associations between CA2/3 volumes and positive symptoms27,30 and 
with one specifically lending some, albeit as of yet weak, support for CA3 involvement in 
hallucinations.23
Post-mortem studies have shown numerous pathophysiological abnormalities that may 
underlie hippocampal formation (HF) circuitry volumetric and physiological abnormalities 
in schizophrenia. For example, immature dentate granule cells60 and lower dentate gyrus 
neural stem cell proliferation have been observed in schizophrenia.61 These findings may 
support Tamminga and colleagues model24 of hypoglutamatergic activity in the dentate 
gyrus and may fit with findings of diminished mossy fiber projections to CA3 in individuals 
with schizophrenia compared to controls.62 In addition, several studies suggest that 
schizophrenia is associated with a lower number of interneurons, possibly resulting in 
disinhibition of hippocampal pyramidal cells in CA2/3 and CA1.63,64 These findings support 
the Benes,21 Behrendt,23 and Small et al20 models. A lower number of interneurons may in 
part account for the high CA1 CBV observed in schizophrenia as translational work in 
rodents has shown that high CA1 CBV is associated with a hyperglutamatergic state.41 
Finally, evidence for lower subicular spine density, dendritic branching, and dendritic 
density in schizophrenia compared to controls65–67 supports the Lisman and Grace model22; 
though contrary findings exist.68
Several limitations of the studies reported to date must be noted. First, the volumetric studies 
predominantly used FreeSurfer versions prior to version 6.0 which included a substandard 
anatomical template.50 Second, none of the published HF subregion studies do date set out 
to test different HF circuitry models. For example, testing for differential involvement of any 
of the subregions requires a multivariate statistical model that takes into account scalar 
differences between the regional volumes and includes a group by region interaction term in 
the statistical model. Third, all reported studies to date employ univariate statistical models 
to compare volumes and no studies have been designed to identify patient subgroups that 
may be relevant to different prognosis, treatment response, or symptom profiles. Finally, 
only a single study statistically controlled for total hippocampal volume to assess regional 
specificity and no studies examined differences in lateralit. This review also has several 
limitations. First, given that the total number of studies reporting on HF subregion volumes 
and physiology is rather small, the review is limited to qualitative report of their findings. 
Second, this qualitative review does not include hippocampal shape studies whose findings 
are challenging to review and considered beyond the scope of the current report.
This review suggests several future directions to advance the aforementioned six questions 
about HF subregion abnormalities in schizophrenia. First, any new morphometry study 
should include scans at submillimeter resolution; at least in the plane perpendicular to the 
longitudinal axis of the hippocampus. Second, associations between HF subregion volumes 
and clinical symptom and cognitive performance scores, which tend to be weak, may benefit 
from metaor mega-analyses such as those performed by the Enhancing NeuroImaging 
Genetics Analysis through Meta-Analysis (ENIGMA) Schizophrenia Working Group5,69 
and the Cognitive Genetics Collaborative Research Organization (COCORO)6 in order to 
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achieve the sample sizes needed for robust findings. Finally, the field as a whole would 
benefit from additional physiological studies as few have been conducted to date.
The area of hippocampal subregion imaging in schizophrenia is still in its infancy, and we 
must caution against overinterpretation of the findings published to date for several reasons. 
First, the CA1 is the largest hippocampal subregion and given that these studies are at the 
cutting edge of what current imaging technology can provide, it may be easier to detect 
effects in large compared to small regions. Second, it is not clear whether our current image 
resolution is sufficient to assess all relevant anatomical variation.70 Third, there are major 
differences in the methods employed by studies and the field is still working toward a 
consensus of best practices.43–45 Fourth, observations in downstream regions may be a 
consequence of abnormalities in less easily observable (eg, smaller) upstream regions. 
Finally, possible confounding factors in imaging must be carefully considered.71 
Nevertheless, continued advances in neuroimaging data collection methods and image 
processing techniques are starting to enable in-vivo investigations of hippocampal subregion 
abnormalities in schizophrenia, and hold promise for a deeper understanding of hippocampal 
circuitry involvement in schizophrenia.
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FIGURE 1. 
Study selection flow diagram
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TABLE 2
Schizophrenia hippocampal physiology studies
Author Year Group (N) Study design Method Hyperactivity
Schobel et al40 2009 SCZ (18)
HC (18)
CSD CBV CA1
CHR-C (11)
CHR-NC (7)
T CA1, L CA1
Schobel et al41 2013 CHR-C (10)
CHR-NC (15)
HC (25)
LD CBV CA1; subiculum↑
Talati et al42 2014 SCZ (15)
HC (15)
CSD CBV CA1a
↓/↑, longitudinal decrease/increase; CA, Cornu Ammonis; CBV, cerebral blood volume; CHR-C, clinical high risk of psychosis converters; CHR-
NC, clinical high risk of psychosis non-converters; CSD, cross-sectional design; HC, healthy control; L, left; LD, longitudinal design; R, right; 
SCZ, schizophrenia; T, total (left and right hemisphere combined).
a
Marginally significant effect (P = 0.06).
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